Scientists develop novel tools to gain new insights into an important therapeutic target
Australian researchers drive global call to action to tackle world’s leading cause of death
Monash University researchers discover potential therapeutic target to reduce diabetes-induced heart failure
Researchers identify off switch for alcoholism
Researchers from Monash University and the Florey Institute have made a potential breakthrough in the ability to treat alcohol addiction with a simple drug.
Professor Mark Febbraio wins the 2020 GSK Award for Research Excellence
Professor Mark Febbraio from the Monash Institute of Pharmaceutical Sciences (MIPS) has become the 40th winner of the prestigious GSK Award for Research Excellence.
Monash University scientist wins prestigious Eureka Prize for ground-breaking research into treating metabolic disease
Professor Mark Febbraio from the Monash Institute of Pharmaceutical Sciences (MIPS) has been awarded the 2020 Australian Museum Eureka Prize, the nation’s top science award.
Leading Australian metabolic disease researcher wins Society of Endocrinology International Medal
Prominent metabolic disease researcher Professor Mark Febbraio, from the Monash Institute of Pharmaceutical Sciences (MIPS), has been awarded the 2021 International Medal from the UK’s Society of Endocrinology.
Breakthrough discovery paves the way for preventing sugar-induced liver disease
A team of international researchers including Monash University academics has discovered that, contrary to previous belief, fructose causes liver toxicity by changing the barrier function of the intestine.
New international collaboration showcases drug development potential
New research from Monash Institute of Pharmaceutical Sciences (MIPS), in collaboration with the Max Planck Institute, Mayo Clinic, University of Auckland, University of Essex and University of Tokyo, has uncovered new structures of protein